One in a million chance of death following AstraZeneca jab: TGA By contrast, Australians aged 60 and over – for whom AstraZeneca is preferred – have a nearly one in 10 chance of dying from COVID.
Clearer picture of long-term vaccine efficacy against severe COVID Major pre-print studies comparing multiple COVID vaccines have found their ability to protect against hospitalisation and death may begin to wane in the long term.
Survey suggests vaccine hesitancy is falling across Australia The results indicate a positive trend, but researchers say more work needs to be done to assess why some people are still not being reached.
Five further blood clot cases linked to AstraZeneca The latest TGA safety report also confirms no vaccine-related fatalities have occurred in the past week, in stark contrast to 62 COVID deaths.
Government clarifies GPs’ position as states expand Pfizer eligibility The Department of Health has confirmed GPs can mirror states on Pfizer eligibility for over-60s.
General practice to follow state Pfizer criteria GPs in South Australia and the Northern Territory will soon begin administering the Pfizer vaccine to over-60s in line with state-run mass vaccination hubs, and other states could soon follow.
No fatalities among seven new AZ blood clots cases The additional cases mean thrombosis with thrombocytopenia syndrome is occurring at a rate of 1.29 per 100,000 doses administered.
Reports of non-GP specialists advising patients to wait for Pfizer GPs say they feel like gatekeepers of Pfizer, with some patients over 60 presenting with exemption letters despite having no contraindications to AstraZeneca.
How high can Australia’s vaccination rate go? With signs the rate of COVID vaccination take-up may be about to plateau, newsGP considers what heights the overall national rate could eventually reach.
ACT latest jurisdiction to reduce AZ dosing interval The COVID outbreak in Canberra means people can get a second dose of AstraZeneca after 4–8 weeks. What does this mean for efficacy?